The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 26, 2021

Filed:

Jan. 17, 2014
Applicant:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Inventors:

Jean-Baptiste Michel, Paris, FR;

Didier Letourneur, Paris, FR;

Frederic Chaubet, Paris, FR;

Laure Bachelet, Paris, FR;

Francois Rouzet, Paris, FR;

Alain Meulemans, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/06 (2006.01); G01N 33/53 (2006.01); A61K 49/22 (2006.01); A61K 49/18 (2006.01); A61K 49/04 (2006.01); G01N 33/68 (2006.01); G01N 33/574 (2006.01); C08B 37/00 (2006.01); C08L 5/00 (2006.01); A61K 49/06 (2006.01); A61K 51/00 (2006.01);
U.S. Cl.
CPC ...
A61K 51/065 (2013.01); A61K 49/04 (2013.01); A61K 49/0438 (2013.01); A61K 49/06 (2013.01); A61K 49/1863 (2013.01); A61K 49/22 (2013.01); A61K 49/221 (2013.01); A61K 49/223 (2013.01); A61K 51/00 (2013.01); C08B 37/0063 (2013.01); C08L 5/00 (2013.01); G01N 33/53 (2013.01); G01N 33/574 (2013.01); G01N 33/6893 (2013.01); G01N 33/6896 (2013.01); G01N 2333/405 (2013.01); G01N 2333/4724 (2013.01); G01N 2400/00 (2013.01); G01N 2800/102 (2013.01); G01N 2800/28 (2013.01); G01N 2800/32 (2013.01);
Abstract

The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.


Find Patent Forward Citations

Loading…